Related Experiment Video
Updated: Jun 6, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepcidin biology and therapeutic applications
1David Geffen School of Medicine, UCLA, 10833 LeConte Ave, CHS 37-131, Los Angeles, CA 90095, USA. enemeth@mednet.ucla.edu.
Expert Review of Hematology
|November 19, 2010
Summary
Hepcidin, a key hormone regulating iron, is crucial in iron disorders. Advances in understanding hepcidin biology offer potential therapeutic applications for iron metabolism diseases.
Area of Science:
- Biochemistry
- Endocrinology
- Hematology
Background:
- Hepcidin is a hepatic peptide hormone that controls iron homeostasis.
- Hepcidin dysregulation is implicated in various iron disorders, including iron overload and anemia.
- Understanding hepcidin's role is vital for addressing conditions like hereditary hemochromatosis, anemias, and chronic kidney disease.
Framework:
- The Scientific Program on Iron and Heme session focused on hepcidin.
- Discussions covered recent advances in hepcidin biology.
- Exploration of potential therapeutic applications of hepcidin was a key theme.
Implementation:
- The session featured three 30-minute presentations.
- Experts shared insights into hepcidin's regulatory mechanisms.
- The program highlighted the clinical relevance of hepcidin research.
Implications:
- Advances in hepcidin research may lead to novel treatments for iron-related diseases.
- Targeting hepcidin could offer new therapeutic strategies for anemia and iron overload.
- Further understanding of hepcidin biology promises to improve patient outcomes in hematology and nephrology.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).